Telomir Other Thursday, September 17, 2026 +0.20 Positive

Publication Shows Telomir-Zn Restores Vision in Retinal Disease Model

Telomir Pharmaceuticals announced peer-reviewed research demonstrating Telomir-Zn's ability to improve visual function and restore retinal structure in an AMD model. The findings validate the company's epigenetic mechanism of action and suggest broader applications beyond cancer.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed